In combination with ipilimumab as first-line treatment for adult patients with metastatic NSCLC expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. This evidence concerns the gene ALK and non-small cell lung carcinoma.